Allogene Therapeutics Inc.

10/29/2024 | Press release | Distributed by Public on 10/29/2024 06:39

Allogene Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for ALLO-316, an AlloCAR T™ Investigational Product for Adult Patients with[...]

Read this content
Click here to read the original version at the source's official website. The text of this article is not available at the moment.